Pharma company pairs with RNA interference specialist

Published: 11-Oct-2007

Alynylam Pharmaceuticals is strengthening its knowledge of RNA interference (RNAi) and transfection thanks to a new alliance it has formed with a specialist in solutions for intracellular delivery of nucleic acids.


Alynylam Pharmaceuticals is strengthening its knowledge of RNA interference (RNAi) and transfection thanks to a new alliance it has formed with a specialist in solutions for intracellular delivery of nucleic acids.

The collaborative agreement will see Alnylam harnessing RNAi therapeutic delivery solutions from Poylplus-transfection.

The companies believe the collaboration has the potential to bring about improvements in the delivery of siRNA therapies.

"A big advantage of this relationship is that Polyplus-transfection will benefit from having its chemical carriers tested in several disease models while working with the most advanced target sequences and mixed chemical siRNA modifications from Alnylam."

Poluplus-transfection is developing several in vivo siRNA formulation solutions based on its lead compounds in vivo-jetPEI and INTERFERin, as well as on an original RNA modification, sticky siRNA.

You may also like